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It is now increasingly recognized that some monogenic autoinflammatory diseases
and immunodeficiencies cause vasculitis, although genetic causes of vasculitis are
extremely rare. We describe a child of non-consanguineous parents who presented
with cutaneous vasculitis, digital ischaemia and hypocomplementaemia. A heterozygous
p.R1042G gain-of-function mutation (GOF) in the complement component C3 gene was
identified as the cause, resulting in secondary C3 consumption and complete absence of
alternative complement pathway activity, decreased classical complement activity, and
low levels of serum C3 with normal C4 levels. The same heterozygous mutation and
immunological defects were also identified in another symptomatic sibling and his father.
C3 deficiency due GOF C3mutations is thus now added to the growing list of monogenic
causes of vasculitis and should always be considered in vasculitis patients found to have
persistently low levels of C3 with normal C4.
Keywords: cutaneous vasculitis, digital ischaemia, autoinflammation, gain-of-function (GOF), next-generating
sequencing, targeted gene capture, complement component (C3, C4)
BACKGROUND
The complement system is an important component of the innate immune system, with several
versatile functions in host defense, immune surveillance, and cell homeostasis (1–3). Deficiencies
of individual complement proteins and complement regulatory proteins are associated with
increased risk of infection, and in some cases autoimmunity (4, 5). C3 deficiency is very rare,
with less than 50 cases described worldwide with varied clinical presentation (6–8). Primary
C3 deficiency due to bi-allelic loss of function mutations in C3 is typically associated with
increased susceptibility to bacterial infections (such as bacterial pneumonia or meningitis) often
manifesting in early childhood; and/or development of immune complex–mediated diseases such
as glomerulonephritis (9–12). Additionally, polymorphisms in theC3 genemay confer an increased
risk for the development of age-related macular degeneration, atypical hemolytic uremic syndrome
(aHUS), dense deposit glomerulonephritis (13–16), or influence outcomes of organ transplantation
(17, 18). Whilst reduced plasma C3 is commonly observed with concomitant reduction in C4 due
to classical pathway activation, for example secondary to autoimmune diseases such as systemic
lupus erythematosus, low plasma C3 with relative conservation of C4 is typical of alternative
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pathway activation, and should always prompt further
investigation for monogenic causes (19, 20). These include
bi-allelic loss of function mutations in C3, or complement factor
I (CFI) (19), but can also be caused by mono allelic gain-of-
function (GOF) C3 mutation (13, 21, 22). Vasculitis caused by
GOF mutation in C3 has never been reported before, however.
Herein, we describe a child of non-consanguineous parents
who presented with cutaneous vasculitis, digital ischaemia
and hypocomplementaemia. A heterozygous p.R1042G GOF
mutation of C3 was identified as the cause, resulting in complete
absence of alternative complement pathway activity, reduced
classical complement activity, and low levels of C3 with normal
C4 levels.
CASE PRESENTATION
The index case was a previously well 6-year-old male, born to
non-consanguineous Caucasian parents (family tree, Figure 1A).
He spontaneously developed acute, painful erythema and
discoloration of his fingers and toes (Figures 2A–C). There
were no reported precipitants, specifically no evidence of any
intercurrent infection, and no past medical history suggestive of
immunodeficiency. On systems review, he reported intermittent
non-peritonitic abdominal pain, and arthralgia of knees and
ankles. He rapidly deteriorated over the next 48 h, developing
critical digital ischaemia of his toes (Figures 2D,E).
Laboratory investigations (Supplemental Table 1) in the
proband revealed normal renal function and blood pressure, and
there was no evidence of proteinuria or other organ specific
involvement. Chest radiograph, abdominal ultrasonography,
echocardiography, and visceral digital subtraction catheter
arteriography were all normal. There was only minor elevation
of the erythrocyte sedimentation rate (13 mm/hour; reference
range [RR] 0-10), and normal C-reactive protein (CRP)<5 mg/L
(RR <20). All full blood count parameters were normal. Blood
film examination was unremarkable. He had low titer antinuclear
antibodies (1:160). Other autoantibodies (rheumatoid factor,
ANCA, including anti-proteinase 3 and anti-myeloperoxidase;
anti-double stranded DNA; anticardiolipin antibodies and lupus
anticoagulant; thyroid peroxidase antibodies; and antibodies
against extractable nuclear antigens) were all negative. Extensive
investigations for an infectious cause of his symptoms were
negative, specifically negative mycoplasma pneumoniae serology;
and he had negative cryoglobulins. A full prothrombotic
workup was also negative. Notably, however, he had persistently
low serum C3 (0.22 g/L; RR 0.75–1.65), and normal C4
(0.21 g/L; RR 0.14–0.54); complete absence of alternative
complement functional activity (0%, RR >10%); and reduced
functional classical pathway activity (31%; RR> 40%; Table 1).
Low C3, normal C4, absent alternative complement pathway
activity, and markedly decreased classical complement pathway
activity persisted, and prompted more detailed scrutiny of the
complement pathway (see below for complement deficiency
work up). Vasodilatory treatment for critical digital ischaemia
included oral nifedipine 40 mg/day with little response, and
subsequently prostacyclin infusion (20 ng/mg/min continuous
infusion over 5 days) to improve the perfusion in his toes. He
was also treated with a short course of oral prednisolone (2
mg/kg/day; weaning over 12 weeks), aspirin (5mg/kg /day) and
oral azathioprine (2 mg/kg/day), on which he currently remains
12 months later. He made a full recovery with no residual
skin lesions or permanent tissue loss. Corticosteroids however
were reintroduced with good response 13 months later as there
was recurrence of finger ischaemia.. C3 remains persistently
decreased 0.22 g/L, with normal C4 0.27 g/L despite ongoing
treatment.
Work Up for Suspected Complement
Deficiency
Table 1 summarizes the genotype and results of complement
studies. All experimental work was performed with ethical
approval (ethics number: 08H071382) and with written informed
consent from all adult participants, assent (where appropriate)
for children, and parental consent for children. C3 and C4
measurements were performed using a standard nephelometry
assay (BN II Siemens Healthcare UK). Classical and alternative
complement assays (EuroDiagnostics, Sweden); MBL assays
(BioPorto) were performed by enzyme-linked immunosorbent
assay (ELISA). Complement factor I and H were measured
at Pathology Imperial College Healthcare, NHS, UK using
ELISA (Binding Site, UK). C1q was measured by radial
immunodiffusion (RID) and C1q antibodies by ELISA at the
Protein Reference Unit Sheffield, UK.
Genetic investigation of the index case (II-1) was performed
using our recently developed targeted gene panel for Vasculitis
and AutoInflammation Panel (VIP) that contains 201 genes,
including 19 pertaining to complement and regulatory proteins
(Supplemental Table 2) (23). This revealed a heterozygous
c.3124C>G (p.R1042G) variant in exon 24 of C3 gene, which
was confirmed by Sanger sequencing (Figure 1B). This variant
is not reported in the population databases (1000 genomes, ESP
6500, and ExAC) and is predicted to be damaging according
to 3 different in silico analysis; SIFT [D], PolyPhen2 [D], and
MutationTaster [D]. There were no other class 4 or 5 genetic
variants detected in any of the other genes included in the
targeted panel for the index case.
Detailed complement studies were undertaken in other
first-degree family members and showed low C3 levels,
absent alternative complement pathway activity, and markedly
decreased classical complement pathway activity in II-2 and
I-1. These studies were normal for I-2 and II-3 (Table 1).
Sanger sequencing in all enrolled family members confirmed
that the heterozygous p.R1042G C3 mutation was also present
in both II-2 and I-1 and absent in I-2 and II-3 (Figures 1A,B).
Interestingly I-1 subsequently developed recurrent cutaneous
vasculitis (purpuric rashes) and arthralgia (Figure 2F) with no
documented renal abnormalities and required corticosteroid
therapy. II-2 was also reporting long standing history of recurrent
fingertip erythema with no other systemic symptoms while I-2
and II-3 were asymptomatic (see Supplemental Table 2 for other
laboratory tests for I-1 and II-2).
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FIGURE 1 | Family tree and Sanger sequencing results. (A) Family tree showing affected and unaffected members enrolled in the study; segregation of the p.R1042G
mutation in C3 with disease is also indicated. Arrow indicates the index case. (B) Sanger sequencing confirmed a heterozygous C/G mutation (blue/black overlapping
line) at position c.C3124 of C3 gene in family members II-1, I-1, and II-2 that is absent (single blue line corresponding to wild type “C” allele) in I-2 and II-3.
FIGURE 2 | Cutaneous vasculitis and digital ischaemia associated with heterozygous gain-of-function mutation in C3. (A–C). Discolouration and erythema in fingers
of both hands and toes of the index case (II-1). (D,E). Digital ischaemic necrosis seen in the second and third digit of the left foot for II-1. (F) Cutaneous vasculitis
affecting I-1.
DISCUSSION
We describe a monoallelic p.R1042G mutation in C3 as the
genetic cause of familial cutaneous vasculitis and severe digital
ischaemia. This mutation has been previously described as a
GOF mutation, associated with glomerulonephritis (24). The
presentation in our patient with digital vasculitis and ischaemia
is therefore unique, and the vasculitic features in other family
members who had the same mutation and immunophenotype
emphasizes that this is a fully penetrant dominant mutation
in this kindred. Thus the spectrum of monogenic vasculitis
continues to expand, andmono-allelic C3GOFmutations should
now be considered in patients with ANCA negative vasculitis,
particularly when associated with low serum C3, but normal C4
levels.
During the activation process of the alternative complement
pathway, C3 undergoes large conformational changes following
the release of C3a by C3 convertase, thereby exposing the
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FIGURE 3 | The activation and regulation of the alternative pathway (AP)
complement component C3. Illustration of C3 molecule is presented in blue,
with ANA domain (C3a) in red triangle, yellow circle for TED domain, and
orange oval for the CUB domain. Major structural changes occurs during C3
activation leading to the release of bioactive fragments C3a and C3b.
Alternative pathway C3 convertase (C3bBb) is then formed by the association
of C3b fragment with complement factor B (FB; illustrated in green) in the
presence of complement factor D (FD). Further activation of C3 then occurs via
the amplification loop. The consumption of AP C3 is regulated by Factor I that
degrades C3b and Factor H that dissociate C3 convertase. Factor H is also
required for the protease activity of Factor I. Low plasma C3 is associated with
bi-allelic loss of function (LOF) mutations in C3 or complement factor I (CFI)
and also by mono allelic gain-of-function (GOF) C3 mutation. The C3
p.R1042G mutation (indicated by an asterisk in the TED domain) leads to the
formation of an abnormal C3 convertase that cannot bind to FH, thereby
amplifying the consumption of C3.
reactive thio-ester containing domain (TED) on the C3b
fragment (Illustrated in Figure 3). The TED on C3b can then
rapidly covalently bind to nucleophiles on cell surfaces (25).
Attachment of the C3b fragment to cell surfaces initiates a
powerful amplification reaction, by interaction with factor B,
factor D and properdin, leading to the formation of more
C3 convertases that use plasma C3 as a substrate (26, 27).
This positive feedback amplification loop, if dysregulated,
results in rapid and uncontrolled consumption of C3, with
major impact on the alternative complement pathway (28,
29), and relative sparing of the classic pathway which can
function with much lower levels of C3 than the alternative
pathway (19). The heterozygous p.R1042G C3 mutation in
our patients is predicted to affect the active TED in the
C3 protein. Structural studies have demonstrated that this
mutation is positioned within the interacting interface of C3
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TED domain with Factor H consecutive complement control
protein (CCP) domains, thereby inhibiting the regulatory
binding of FH to the alternative pathway C3 convertase (i.e.,
C3bBb) to suppress the amplification loop (30, 31). Thus, the
p.R1042G C3 mutation is predicted to reduce plasma C3 levels
by generating abnormal alternative pathway C3 convertases
(C3bBb) which cannot be inactivated by FH, and leading to rapid
consumption of the normal C3 encoded by the normal allele
(24, 30).
The heterozygous p.R1042G C3 mutation we identified in
our kindred was previously described in a single case of
a 45 year old Spanish male patient who developed mild
proteinuria and microscopic haematuria, but who had no
other symptoms or cutaneous manifestations (24). At the
time of writing, none of our patients have yet developed
renal involvement, but close monitoring of blood pressure,
renal function and urinalysis has been initiated in all family
members with the heterozygous p.R1042GC3 genotype.Whether
renal histopathological abnormalities precede the development
of more typical renal function abnormalities could not be
established for our cases since a renal biopsy was not clinically
indicated or justifiable. Of note, II-2, also heterozygote for
the p.R1042G GOF C3 mutation, has abnormal alternative
and classical complement function, and low C3 levels but is
currently presenting with a milder phenotype suggesting some
variability in the type of clinical manifestations associated with
GOF C3 mutation. Additional genetic and/or environmental
risk factors (such as intercurrent infection or other trigger)
may play a role in modifying the observed phenotype. It is
likely that complement regulatory molecules act as a protein
network and that multiple hits, probably involving plasma
and membrane associated complement regulatory proteins, are
required to significantly impair protection to host tissues. As such
an individual’s complotype could influence susceptibility to, or
severity of, diseases such as C3 deficiency (31–34).
Therapeutic options for the inflammatory manifestations
associated with GOF C3 mutations and resultant secondary
C3 deficiency are very limited, but so far our index case
has remained stable on treatment with vasodilation, anti-
aggregation (aspirin) and immunosuppression. Since the effects
of complement are associated with inflammatory sequelae (such
as vasculitis) but also possible immune deficiency, we chose
a medium strength immunosuppressant to ultimately work
alongside corticosteroids eventually working as steroid sparing
agent. More targeted complement-modulating agents such as
eculizumab, or avacopanmight be worthy of consideration, albeit
with a limited scientific rationale/evidence-base. Eculizumab
is a humanized monoclonal antibody that binds C5 and
prevents assembly of the membrane attack complex (C5b-9)
thereby blocking the final complement cascade and reducing
uncontrolled activation of the alternative complement pathway
(35). Several case reports and open-label studies have already
shown a potential benefit of eculizumab for patients with
C3 glomerulonephritis and aHUS where there is an acquired
dysregulation of complement factors (35–38). In addition,
avacopan, a C5a receptor inhibitor, downregulates activation of
the alternative complement pathway and has been shown to be an
effective add-on therapy for ANCA associated vasculitis (39, 40).
Therefore, these complement modulating agents may also have
a role in treating autoimmunity/autoinflammation associated
with GOF C3mutations via reduction of uncontrolled activation
of the alternate complement pathway. An alternative approach
would be to use plasma exchange to remove dysfunctional C3.
However, membrane-bound abnormal C3, which is responsible
for alternative pathway activation, cannot be eliminated by
plasma exchange, and continued supplementation of C3 may
enhance further complement activation. Lastly, for other cases
of C3 deficiency secondary to genetic defects affecting the
complement regulatory proteins factor H and I, orthotopic
liver transplantation has also been trialed albeit with variable
success, given that these proteins are mainly produced in
the liver. Such an approach, however, is unlikely to be
relevant for patients with GOF C3 mutations given that C3
is not only synthesized in the liver but is also synthesized
by immune cells (41), adipocytes (42), and neuronal cells
(43).
We felt that our patients suffered cutaneous vasculitis despite
the lack of confirmatory biopsy findings. It is now well accepted
that histological confirmation is not needed to diagnose vasculitis
(44), and that clinical diagnoses based on a sound understanding
of pathogenesis (in this case consumptive C3 disease from C3
gain of function and presumed immune complex formation
injury to small vessels in the peripheries) provides justification
to describe this as a vasculitis. In addition, the father (I-1)
developed palpable purpura (see Figure 2F) and typical vasculitic
lesions and has an ESR of 65 mm/h (see Supplemental Table 1);
the sibling II-2 with more minor symptoms of the fingers also
has an elevated ESR of 60 mm/h, confirming the inflammatory
component to this pathology.
Lastly, we cannot completely exclude the possibility that anti-
C1q antibodies might play some secondary role in (II-1 and I-
1) to explain the observed phenotype, although their presence
may represent a non-specific epiphenomenon secondary to
chronically increased complement activation, particularly in view
of normal C1q levels observed in these individuals, and the fact
that C1q antibodies have also been observed non-specifically in
complement factor deficiency (19).
In summary, we expand the spectrum of monogenic
complement deficiencies that cause vasculitis by describing a
family with monoallelic p.R1042G mutation in C3 causing
cutaneous vasculitis and digital ischaemia. Heterozygous GOF
mutations in C3 are now added to the list of genetic complement
deficiencies causing vasculitis such as C1q, C1r, and C1s
deficiency, complement factor I deficiency and complement C2
and C4 deficiency (1, 7, 19). The therapeutic role of complement
inhibition therapies to prevent or reduce tissue damage caused by
dysregulated complement activation in this setting remains to be
established.
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